{"id":"hbsag","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain or swelling"},{"rate":"1-6","effect":"Fever"},{"rate":"1-11","effect":"Fatigue"},{"rate":"1-11","effect":"Headache"},{"rate":"1-17","effect":"Myalgia"}]},"_chembl":null,"_dailymed":{"setId":"468b1ba5-371c-4ff0-8565-06482771fc25","title":"HEPATITIS B SURFACE ANTIGEN (HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN) LIQUID [MERCK SHARP & DOHME CORP.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HBsAg functions as a vaccine antigen by presenting the hepatitis B surface protein to the immune system, triggering both humoral (antibody) and cellular immune responses. This leads to the production of anti-HBs antibodies that provide protection against hepatitis B virus infection. The antigen is typically derived from recombinant DNA technology or plasma-derived sources.","oneSentence":"HBsAg is a hepatitis B surface antigen used as an immunogen to stimulate the body's immune system to produce protective antibodies against hepatitis B virus infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:11:47.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals"}]},"trialDetails":[{"nctId":"NCT05551273","phase":"PHASE2","title":"Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-05","conditions":"Hepatitis B, HIV Infections","enrollment":29},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT06958198","phase":"PHASE1","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a \"Multi-stage\" Malaria Vaccine)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-15","conditions":"Malaria,Falciparum","enrollment":56},{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":240},{"nctId":"NCT05856890","phase":"PHASE1","title":"HepB mAb19 in Individuals With Chronic Hepatitis B Infection","status":"RECRUITING","sponsor":"Rockefeller University","startDate":"2023-08-07","conditions":"Hepatitis b Virus, Hepatitis B","enrollment":37},{"nctId":"NCT06786429","phase":"PHASE4","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","status":"NOT_YET_RECRUITING","sponsor":"Eunice Dube","startDate":"2026-08-30","conditions":"Hepatitis B, Human Papilloma Virus, Gall Stones (& [Calculus - Gall Bladder])","enrollment":1800},{"nctId":"NCT03149627","phase":"","title":"Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-06-07","conditions":"HBV, Alcoholic Hepatitis, Liver Fibroses","enrollment":5003},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":"Hepatitis B, Chronic","enrollment":58},{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":"Malaria, Malaria Vaccine, Insecticide-treated Bednets","enrollment":1691},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT07328711","phase":"EARLY_PHASE1","title":"Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Chronic Hepaititis B","enrollment":132},{"nctId":"NCT02349126","phase":"PHASE2","title":"Study of ARC-520 in Patient With Chronic Hepatitis B Virus","status":"WITHDRAWN","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT06347588","phase":"","title":"Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-06-06","conditions":"Occult Hepatitis B Infection in Cancer Patients","enrollment":60},{"nctId":"NCT01198860","phase":"","title":"Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B","status":"APPROVED_FOR_MARKETING","sponsor":"Nguyen Thi Trieu, MD","startDate":"","conditions":"CHRONIC HEPATITIS B","enrollment":""},{"nctId":"NCT07258251","phase":"PHASE4","title":"Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","status":"NOT_YET_RECRUITING","sponsor":"The Task Force for Global Health","startDate":"2026-01-01","conditions":"Chronic Hepatitis B, Hepatitis B Virus Infection","enrollment":6000},{"nctId":"NCT07257562","phase":"","title":"Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-06-01","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT02743182","phase":"NA","title":"HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients","status":"COMPLETED","sponsor":"José Antonio Carrion","startDate":"2015-01","conditions":"Chronic Hepatitis B (HBeAg-negative)","enrollment":119},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT03910972","phase":"PHASE1, PHASE2","title":"Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-10-07","conditions":"Schistosomiasis, Schistosoma Mansoni","enrollment":290},{"nctId":"NCT02452528","phase":"PHASE2","title":"Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT04843852","phase":"PHASE1","title":"TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-10-16","conditions":"Hepatitis B, Chronic Hepatitis B","enrollment":10},{"nctId":"NCT07204236","phase":"EARLY_PHASE1","title":"Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grand Theravac Life Sciences (Nanjing) Co., Ltd.","startDate":"2024-01-18","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT05769816","phase":"PHASE2","title":"A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)","status":"RECRUITING","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2023-10-10","conditions":"Chronic Hepatitis b, Anti-PD-1 Antibody","enrollment":120},{"nctId":"NCT05771402","phase":"PHASE2","title":"A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)","status":"RECRUITING","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2023-10-10","conditions":"Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNα","enrollment":120},{"nctId":"NCT05345990","phase":"PHASE2","title":"Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2022-08-15","conditions":"Chronic Hepatitis B","enrollment":13},{"nctId":"NCT05613621","phase":"","title":"Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2025-08-14","conditions":"Hepatocellular Carcinoma","enrollment":579},{"nctId":"NCT07116044","phase":"","title":"Assessment of Response and Safety of Bulevirtide Treatment in Patients With Chronic Delta Virus Infection","status":"COMPLETED","sponsor":"University of Molise","startDate":"2023-06-15","conditions":"Evaluate Response to Treatment Both Biochemically and Virologically to Determine the Safety and Effectiveness of Bulevirtide Therapy in HDV Patients","enrollment":160},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT07088133","phase":"NA","title":"Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-08-01","conditions":"HBV Infection, HCC - Hepatocellular Carcinoma","enrollment":12},{"nctId":"NCT06537414","phase":"PHASE2","title":"A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"Chronic Hepatitis B Virus Infection, Hepatitis B","enrollment":283},{"nctId":"NCT07085715","phase":"","title":"Pan-Viral Screening and Linkage to Care Among GBMSM and Trans Women in Spain","status":"NOT_YET_RECRUITING","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2025-10","conditions":"HIV, Hepatitis B, Hepatitis C","enrollment":500},{"nctId":"NCT04942886","phase":"NA","title":"Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Seoul St. Mary's Hospital","startDate":"2021-08-21","conditions":"Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation, Antiviral Drug","enrollment":226},{"nctId":"NCT07071636","phase":"PHASE4","title":"Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-08-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Chronic Hepatitis B","enrollment":830},{"nctId":"NCT07053449","phase":"","title":"The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical Harms","status":"NOT_YET_RECRUITING","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2025-08","conditions":"Hepatitis B Virus (HBV)","enrollment":30},{"nctId":"NCT07054359","phase":"NA","title":"\"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission\"","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-11","conditions":"HBV Infection, Pregnancy","enrollment":3200},{"nctId":"NCT05550519","phase":"EARLY_PHASE1","title":"A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment","status":"WITHDRAWN","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2022-10-31","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT06755632","phase":"NA","title":"Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-06-19","conditions":"Liver Pathology","enrollment":600},{"nctId":"NCT07010198","phase":"","title":"Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City","status":"RECRUITING","sponsor":"Zhongshan People's Hospital, Guangdong, China","startDate":"2025-03-01","conditions":"Hepatocellular Cancer (HCC)","enrollment":4500},{"nctId":"NCT05446532","phase":"","title":"Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes","status":"COMPLETED","sponsor":"Corporacion Parc Tauli","startDate":"2022-06-15","conditions":"Hepatitis B","enrollment":120},{"nctId":"NCT06216470","phase":"PHASE2","title":"Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-03-13","conditions":"Hepatitis B, Chronic","enrollment":15},{"nctId":"NCT05936073","phase":"","title":"DELTA DESCRIBE: the French Collaborative Project","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2024-01-22","conditions":"Hepatitis D","enrollment":734},{"nctId":"NCT06966908","phase":"","title":"Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-01-03","conditions":"Chronic Hepatitis B","enrollment":16000},{"nctId":"NCT01808352","phase":"","title":"HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2013-08-15","conditions":"HIV","enrollment":226},{"nctId":"NCT05727267","phase":"PHASE1","title":"A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2024-01-23","conditions":"Chronic Hepatitis B","enrollment":24},{"nctId":"NCT04035837","phase":"PHASE4","title":"The Clinical Cure Project of Chronic Hepatitis B in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-05-16","conditions":"Hepatitis B, Chronic","enrollment":30000},{"nctId":"NCT04954859","phase":"PHASE2","title":"Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-12-14","conditions":"Hepatitis B","enrollment":450},{"nctId":"NCT06900166","phase":"PHASE4","title":"Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-04-01","conditions":"Chronic Hepatitis B","enrollment":360},{"nctId":"NCT03899428","phase":"PHASE2","title":"Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC","status":"RECRUITING","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-02","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT06876467","phase":"","title":"Study of the Cellular Response Induced After Vaccination Against the Hepatitis B Virus","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04-01","conditions":"Hepatitis B Vaccination, Immune Response, T Cells","enrollment":115},{"nctId":"NCT03804372","phase":"PHASE2","title":"The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide","status":"TERMINATED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2020-07-07","conditions":"Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia","enrollment":5},{"nctId":"NCT06368479","phase":"NA","title":"Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings","status":"COMPLETED","sponsor":"bioLytical Laboratories","startDate":"2024-03-19","conditions":"Hepatitis B, Hepatitis B Infection","enrollment":1400},{"nctId":"NCT06368466","phase":"NA","title":"A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites","status":"COMPLETED","sponsor":"bioLytical Laboratories","startDate":"2024-04-30","conditions":"Hepatitis B, Hepatitis B Infection","enrollment":175},{"nctId":"NCT05417932","phase":"PHASE1, PHASE2","title":"A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"SCG Cell Therapy Pte. Ltd.","startDate":"2022-10-26","conditions":"Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma Recurrent","enrollment":46},{"nctId":"NCT06800131","phase":"PHASE1","title":"Hepatitis B Vaccine Delivered Trans-dermally by MAP","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-02-05","conditions":"Hepatitis B Vaccine","enrollment":40},{"nctId":"NCT02766933","phase":"","title":"Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-05","conditions":"Hepatitis B, Hepatitis B, Chronic","enrollment":207},{"nctId":"NCT05956314","phase":"PHASE1","title":"Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC","status":"COMPLETED","sponsor":"Kamari Pharma Ltd","startDate":"2023-03-06","conditions":"Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita","enrollment":18},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT06539052","phase":"","title":"MIGrant Reflex Test HDV (MIGRED) Project","status":"NOT_YET_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2024-12-20","conditions":"Hepatitis D Virus Infection","enrollment":7500},{"nctId":"NCT04914611","phase":"","title":"Real World Assessment of People Living With Chronic Hepatitis B in Australia","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2022-02-17","conditions":"Hepatitis B","enrollment":10000},{"nctId":"NCT04735549","phase":"NA","title":"Vulvovaginal Atrophy Correction Using Neodymium Laser","status":"COMPLETED","sponsor":"MeLSyTech, Ltd","startDate":"2021-09-01","conditions":"Postmenopausal Period, Vaginal Atrophy, Female Urogenital Diseases","enrollment":120},{"nctId":"NCT05463081","phase":"NA","title":"Clinical Trial of \"Magic Gyno\" Laser Device","status":"COMPLETED","sponsor":"MeLSyTech, Ltd","startDate":"2022-08-05","conditions":"Female Urogenital Diseases, Urinary Incontinence, Prolapse Genital","enrollment":70},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT04904835","phase":"","title":"Access HBV Assays - European Union (EU) Clinical Trial Protocol -","status":"RECRUITING","sponsor":"Beckman Coulter, Inc.","startDate":"2019-10-15","conditions":"HBV","enrollment":21210},{"nctId":"NCT06047093","phase":"NA","title":"Fine Needle Aspiration (FNA) Evaluation of the Intrahepatic HBV Reservoir and Its Immunological Characteristics in Chronically HBV-infected Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-03-08","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT06696664","phase":"","title":"Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon","status":"RECRUITING","sponsor":"Minghui Li","startDate":"2024-08-01","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT04619082","phase":"PHASE4","title":"TAF to Prevent HBV Reactivation in Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiayi Christian Hospital","startDate":"2021-07-01","conditions":"Hepatitis B Reactivation","enrollment":102},{"nctId":"NCT06676410","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2023-07-20","conditions":"HIV, HIV Infection","enrollment":40},{"nctId":"NCT05978037","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-08-18","conditions":"Malaria, Malaria,Falciparum, Parasitic Disease","enrollment":58},{"nctId":"NCT05867056","phase":"PHASE1","title":"Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection","status":"WITHDRAWN","sponsor":"Immunocore Ltd","startDate":"2020-08-12","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT05350865","phase":"","title":"Thailand HDV Cohort","status":"RECRUITING","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2023-01-30","conditions":"HDV","enrollment":3152},{"nctId":"NCT06618573","phase":"PHASE2, PHASE3","title":"Safety of Administering Isoniazid to SLE Patients to Prevent TB","status":"RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2022-08-15","conditions":"Tuberculosis, Systemic Lupus Erythematosus","enrollment":60},{"nctId":"NCT06617000","phase":"PHASE1","title":"A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related","status":"RECRUITING","sponsor":"SCG Cell Therapy Pte. Ltd.","startDate":"2022-10-25","conditions":"HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT03772249","phase":"PHASE1","title":"Study of Safety and Tolerability of DCR HBVS","status":"COMPLETED","sponsor":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","startDate":"2018-12-28","conditions":"Hepatitis B, Chronic","enrollment":82},{"nctId":"NCT06586983","phase":"","title":"Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-09-04","conditions":"Hepatitis B","enrollment":4500},{"nctId":"NCT06579313","phase":"","title":"Current Situation of Health Care in Women With HBV or HCV Infection","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"HBV, HCV","enrollment":2500},{"nctId":"NCT06573190","phase":"","title":"Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Yaşar Bayındır, MD","startDate":"2023-01-02","conditions":"Chronic Hepatitis B, Hepatic Steatosis","enrollment":70},{"nctId":"NCT06550622","phase":"","title":"Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-08-10","conditions":"Hepatitis B, Chronic","enrollment":300},{"nctId":"NCT06248580","phase":"","title":"Find HDV and Determine Its Status in Turkey","status":"RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2024-03-11","conditions":"Chronic Hepatitis D Infection, Fibrosis, Liver, Hepatocellular Carcinoma","enrollment":20000},{"nctId":"NCT06544551","phase":"PHASE3","title":"Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Beijing Kawin Technology Share-Holding Co., Ltd.","startDate":"2021-12-28","conditions":"Chronic Hepatitis B Virus Infection","enrollment":336},{"nctId":"NCT03934736","phase":"PHASE1","title":"HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2019-04-22","conditions":"End Stage Renal Disease on Hemodialysis (Diagnosis)","enrollment":119},{"nctId":"NCT06525909","phase":"","title":"A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-01-20","conditions":"Hepatitis B, Chronic","enrollment":250},{"nctId":"NCT06503796","phase":"PHASE4","title":"Antiviral Therapy in Infants With HBV Infection","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-08","conditions":"HBV","enrollment":60},{"nctId":"NCT04661579","phase":"PHASE2","title":"Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy","status":"COMPLETED","sponsor":"PATH","startDate":"2020-11-06","conditions":"Plasmodium Falciparum","enrollment":620},{"nctId":"NCT06159062","phase":"PHASE1","title":"A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Yangshengtang Co., Ltd","startDate":"2024-06-03","conditions":"Chronic Hepatitis B Virus Infection","enrollment":1},{"nctId":"NCT04456504","phase":"PHASE4","title":"HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-09-15","conditions":"Healthcare Worker, Hepatitis B Vaccine, Nonresponder","enrollment":49},{"nctId":"NCT06424002","phase":"PHASE4","title":"The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children","status":"NOT_YET_RECRUITING","sponsor":"Kamuzu University of Health Sciences","startDate":"2024-06-01","conditions":"Malaria,Falciparum","enrollment":5400},{"nctId":"NCT06403657","phase":"NA","title":"DEcentralize Testing, Education, and Linkage to Care by Using Electronic Best Practice Advisory for Hepatitis B (DETECT-B)","status":"NOT_YET_RECRUITING","sponsor":"Vietnam Viral Hepatitis Alliance","startDate":"2024-05","conditions":"Viral Hepatitis B","enrollment":30},{"nctId":"NCT05453435","phase":"PHASE2","title":"Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-15","conditions":"Resolved Hepatitis B, CD20 Positive B-cell Lymphoma","enrollment":84},{"nctId":"NCT06313255","phase":"","title":"A Retrospective Observational Study on the Effects of Probiotics on HBsAg Clearance","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-05-09","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT06368882","phase":"PHASE4","title":"Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-01-01","conditions":"Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b","enrollment":1500},{"nctId":"NCT04231565","phase":"NA","title":"Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-06-04","conditions":"Hepatitis B Virus","enrollment":200},{"nctId":"NCT05977283","phase":"","title":"HBsAg Declined Patients Follow-up Study","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-05-11","conditions":"Hepatitis B, Hepatitis B, Chronic","enrollment":100},{"nctId":"NCT01721798","phase":"NA","title":"Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women","status":"COMPLETED","sponsor":"FHI 360","startDate":"2013-11-10","conditions":"HIV","enrollment":199},{"nctId":"NCT04640129","phase":"PHASE4","title":"HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-01-01","conditions":"Liver Fibrosis","enrollment":336},{"nctId":"NCT06209398","phase":"PHASE4","title":"Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2018-05-24","conditions":"Hand, Foot and Mouth Disease","enrollment":510}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"PAIN"},{"count":3,"reaction":"DYSPHAGIA"},{"count":2,"reaction":"ADVERSE EVENT"},{"count":2,"reaction":"ARTERIOSCLEROSIS CORONARY ARTERY"},{"count":2,"reaction":"ARTHROPATHY"},{"count":2,"reaction":"ASTHMA"},{"count":2,"reaction":"BACK PAIN"},{"count":2,"reaction":"CANDIDA INFECTION"},{"count":2,"reaction":"COLORECTAL ADENOMA"},{"count":2,"reaction":"DRUG INTOLERANCE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["hepatitis B vaccine based on hepatitis B surface antigen"],"phase":"marketed","status":"active","brandName":"HBsAg","genericName":"HBsAg","companyName":"Vaxine Pty Ltd","companyId":"vaxine-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HBsAg is a hepatitis B surface antigen used as an immunogen to stimulate the body's immune system to produce protective antibodies against hepatitis B virus infection. Used for Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}